Somite.ai
AI-based Platform to Produce Human Tissue for Cell-based Therapies
Company Overview
Snapshot
Founded in October 2023 by Micha Breakstone, Olivier Pourquie, Jay Shendure, Allon Klein, Cliff Tabin, and Jonathan Rosenfeld, Somite.ai operates with 11–50 employees. The company has raised $57.5 million across 3 funding rounds from 16 investors. In May 2025, Somite.ai secured a significant Series A funding round.
Business overview
Somite.ai is developing an AI-based platform to produce human tissue for cell-based therapies, aiming to become a leader in stem cell biology. The company's core technology, AlphaStem, is an AI foundation model designed to enable the scalable creation of new cell therapies. Somite.ai serves the health tech and life sciences markets, focusing on developing treatments for diseases such as Duchenne muscular dystrophy (SMT-M01 program) and metabolic disorders (SMT-B01 program), operating within the Pharma & Medical Biotechnology and Biomaterials & Tissue Engineering sectors.
Strategic signal
In May 2025, Somite.ai secured a $47.5 million Series A funding round, which signals strong investor confidence in its AI platform for cell therapy development. This substantial capital infusion is expected to accelerate the expansion of its AlphaStem platform and advance its pipeline programs, positioning the company for significant growth in the burgeoning field of AI-driven regenerative medicine.
Log in to access full profile ›Company Intelligence Q&A
- What was a key funding event for Somite.ai in 2025?
- In May 2025, Somite.ai secured a $47.5 million Series A funding round. This round was led by Khosla Ventures.
- When was Somite.ai founded and by whom?
- Somite.ai was founded in October 2023 by Micha Breakstone, Olivier Pourquie, Jay Shendure, Allon Klein, Cliff Tabin, and Jonathan Rosenfeld.
- What is the primary focus of Somite.ai's technology?
- Somite.ai focuses on developing AI foundation models, such as AlphaStem, to produce human tissue for cell-based therapies at scale, targeting diseases like diabetes, obesity, and muscular dystrophies.
- What was a notable funding event for Somite.ai in April 2024?
- In April 2024, Somite.ai raised funding in a pre-seed round led by TechAviv Founder Partners.
- What is the company's strategic vision regarding stem cell biology?
- Somite.ai aims to become the 'OpenAI of stem cell biology' by leveraging AI to revolutionize the production of human cells for therapeutic applications.